News Daily News Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman Todd Neale November 01, 2019
News Conference News TCT 2019 AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups Todd Neale September 26, 2019
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2019 LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17 Todd Neale September 10, 2019
News Conference News ESC 2019 For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI Todd Neale September 03, 2019
News Conference News ESC 2019 AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD Todd Neale September 02, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019
News Daily News Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI? Michael O'Riordan July 03, 2019
News Conference News SCAI 2019 Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib Yael L. Maxwell May 24, 2019
News Daily News Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works Shelley Wood April 16, 2019
News Conference News ACC 2019 AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI Caitlin E. Cox March 17, 2019
News Daily News Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests Todd Neale January 09, 2019